BioSpace News Archive

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for two separate Phase 2 clinical studies to study the potential of Ampligen as both an infusion and an intranasal therapy for early-onset COVID-19, the disease caused by SARS-CoV-2.

SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI).

Spineology Inc., an innovator in anatomy-conserving surgery, is excited to launch the Duo Ti Expandable Interbody Fusion Procedure, which combines Spineology’s proprietary mesh technology with porous titanium to deliver a large, anatomy conforming implant via anatomy-conserving lateral decubitus and prone approaches.

Invenio Imaging announced today that it has obtained the CE Mark for the NIO Laser Imaging System according to the In Vitro Diagnostic Directive (IVDD).

Research presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo shows that a new test could identify healthcare professionals who are experiencing high levels of work-related stress and anxiety.

BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announced that a previously unknown role of gelsolin in a signaling system in macrophages was published in the Journal of Immunology.

RMJ Holdings, LLC (RMJH), today announced that data on its first drug candidate RMJH-111B, a novel drug candidate for essential hypertension, is being presented in a poster at the American Heart Association’s Hypertension 2021 Scientific Sessions.

AgaMatrix Holdings LLC d/b/a WaveForm Diabetes, a leader in innovative solutions for glucose monitoring, announces their selection for an oral presentation at the annual European Association for the Study of Diabetes meeting.

LifeNet Health, the world leader in allograft biologics, has optimized its industry-leading cellular bone matrix for minimally invasive surgery with the launch of ViviGen® MIS Delivery System, a major improvement in precision, efficiency and reliability over traditional bone-graft delivery.

Vaxcyte, Inc. announced that Company management will participate in a fireside chat at the Guggenheim 2nd Annual Vaccine and Infectious Disease Conference on Tuesday, October 5, 2021 at 11:30am ET.